AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$LXEO

Otero Jose Manuel sold $6K of LXEO

Otero Jose Manuel (Chief Operating Officer) sold 1,304 shares of Lexeo Therapeutics, Inc. (LXEO) at $4.96 on 2026-08-18.

Original reporting
SEC EDGAR · Otero Jose Manuel
Published Aug 19, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LXEO
Neutral
high confidence
Mentioned
$LXEO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LXEONeutralLow
01

Why it matters

The sale represents a modest reduction in insider stake, unlikely to affect market perception.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: post-market 2026-08-18

Background

Form 4 filings disclose insider trades; investors monitor for material changes.

Company-level read

Ticker impact

$LXEONeutralHigh confidence
Context

COO Jose Manuel Otero sold 1,304 shares for $6,464, a routine insider sale disclosed via Form 4.

Expected impact

No material impact on LXEO stock price.

Evidence & confidence

The transaction size is small relative to total holdings and market cap; typical for insiders.

Market effects

Sector

None; isolated insider transaction.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even small insider sales can signal lack of confidence, but context suggests routine liquidity.

Key entities

  • Company
    Lexeo Therapeutics, Inc.

    Biotech firm listed on NASDAQ under LXEO.

  • Insider
    Jose Manuel Otero

    Chief Operating Officer of Lexeo Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LXEO insider trading history →

Related articles

SEP 22
$LXEOMed

Why is Lexeo Therapeutics stock gaining today?

Lexeo Therapeutics (LXEO) stock rose 4.2% pre-market after announcing strategic transactions, including the acquisition of Mantle Therapeutics for up to $21.3M. The deal adds four FA programs to its pipeline, with LX3010 showing early positive data. Lexeo also entered three research collaborations and maintained its cash runway guidance. Raymond James reiterated a Strong Buy rating and $24.00 price target.

investing.com2 min
SEP 22
$LXEOHighAI 8/10

Lexeo stock rises on $21.3M Mantle deal for FA therapies

Lexeo Therapeutics (NASDAQ:LXEO) shares rose 5.4% premarket after announcing a deal to acquire Mantle Therapeutics for up to $21.3M, expanding its Friedreich ataxia treatment platform. The acquisition includes four therapeutic programs, with $8.3M upfront payment and $13M in potential milestones. Lexeo also launched three research collaborations and expects to submit an IND in 2027. Raymond James reiterated a Strong Buy rating and $24.00 price target.

investing.com1 min
AUG 12
$LXEOMed

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics (Nasdaq: LXEO) reported Q2 2026 results and updates. It finalized SUNRISE-FA 2 protocol and SAP for LX2006, with first patient enrolled in June and site activation ongoing. CLARITY-FA enrollment continues. FDA granted RMAT for LX2020. Cash and investments were $234.2M, funding operations into 2028. R&D was $19.0M and net loss $25.9M ($0.30/share).

finanznachrichten.de4 min
AUG 12
$LXEOMed

Lexeo Therapeutics, Inc. (LXEO): Results of Operations and Financial Condition

Lexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated

SEC EDGAR 8-K5 min
AUG 5
$LXEOMedAI 9/10

Lexeo's heart gene therapy gets FDA status after interim data

Lexeo Therapeutics (Nasdaq: LXEO) said the FDA granted RMAT designation to its AAV-based gene therapy LX2020 for PKP2-associated arrhythmogenic cardiomyopathy, based on interim data from the HEROIC-PKP2 Phase I/II trial. Lexeo also noted Orphan Drug and Fast Track status. RMAT may support accelerated approval, priority review, and rolling review.

stocktitan.net4 min